3R Pharma

3R Pharma Overview

3R Pharma is developing high-end and complex cannabinoid-based pharmaceutical products to address chronic ocular diseases for patients around the world. These patent-pending cannabinoid-based medicines provide a novel treatment option for various conditions that are currently insufficiently addressed. The company's R&D unit, based in Israel, is licensed to conduct scientific and clinical research on cannabinoid formulations by the Ministry of Health IMC.

Cumulative Funding Raised Over Time ($)

Latest News

Feb 20, 2023 · 3rpharma.com

growth-positive

3R Pharma Ltd. Announces the Appointment of Prof. Avi Solomon to its Scientific Advisory Board - 3R pharma

Prof. Avi Solomon has joined 3R Pharma Ltds Scientific Advisory Board to provide strategic guidance and clinical expertise for the companys research and development programs. 3R Pharma is a preclinical-stage pharmaceutical company focused on developing novel cannabinoid-based therapies for ophthalmic diseases. Prof. Solomon is an Associate Professor in the Ophthalmology Department at the Hadassah – Hebrew University Medical Center and specializes in ocular surface disorders and ocular surface diseases. His expertise will help 3R Pharma advance their pipeline of innovative therapies for serious ophthalmic conditions. The company is committed to bringing life-changing treatments to patients in need and improving their quality of life.

Partners

Feb 19, 2023 · 3rpharma.com

growth-positive

3R Pharma announces follow on investment from the "Israeli Innovation Authority" and "CanNegev" Incubator - 3R pharma

3R Pharma Ltd has received a follow-on investment from the Israeli Innovation Authority and CanNegev Start-Ups Incubator. The funding will be used to accelerate the companys drug development programs and advance its lead candidate into clinical trials. The investment is a testament to the progress made by 3R Pharma in advancing its drug development programs. Dry Eye and ocular surface diseases affect a significant portion of the population, and the global market for dry eye syndrome treatment and management is expected to reach USD 7.73 billion by 2027. 3R Pharmas lead candidate is a cannabinoid derived from cannabis plants that targets inflammatory pathways in the ocular surface of the eye. The company is focused on developing novel cannabinoid-based therapies for ophthalmic diseases.

Investment

Dec 15, 2021 · 3rpharma.com

growth-positive

3R Pharma announces seed investment - 3R pharma

3R Pharma, a biopharmaceutical company focused on ophthalmological conditions, has announced seed investment. The company has partnered with the CanNegev incubator, which is a joint venture between BOL Pharma, Perrigo, OurCrowd, and the Israeli Innovation Authority. The seed funding will be used to develop ophthalmic therapy based on active ingredients of the cannabis plant. 3R Pharma is located in Yeruham and will have access to office space and a fully equipped lab provided by the incubator. The founder and CEO, Michael Rubinov, expressed excitement about the investment and the companys product vision.

InvestmentPartners

Funding

Team Members

4

Employees: 1-10

Web & Social Links

Locations

Yeruham, Israel

Photos & Videos

No files yet

3R Pharma Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info